Toggle light / dark theme

Gearing up for the interview with Harold Katcher!


Epigenetic age reversed by 54%. Scientific trial by Horvath Clock.

In this video we will discuss a paper entitled “Reversing age: dual species measurement of epigenetic age with a single clock”.
The paper can be found here https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1.full.

The paper is a preprint available on bioXriv on a study showing the reversal of age in rats through exchange of blood plasma. Blood plasma of older rats was exchanged for that of younger rats which lead to the older rats having a reduced epigenetic age and many improved biomarkers, including reduced inflammation.

The age of the rats’ tissue was assessed by Dr Steve Horvath using 6 separate clocks which covered individual tissue as well as a pan tissue clocks.

An anthropologist dives into the world of genetic engineering to explore whether gene-editing tools such as CRISPR fulfill the hope of redesigning our species for the better.


The Mutant Project: Inside the Global Race to Genetically Modify Humans by Eben Kirksey. St. Martin’s Press, November 2020. Excerpt previously published by Black Inc.

Surreal artwork in the hotel lobby—a gorilla peeking out of a peeled orange, smoking a cigarette; an astronaut riding a cyborg giraffe—was the backdrop for bombshell news rocking the world. In November 2018, Hong Kong’s Le Méridien Cyberport hotel became the epicenter of controversy about Jiankui He, a Chinese researcher who was staying there when a journalist revealed he had created the world’s first “edited” babies. Select experts were gathering in the hotel for the Second International Summit on Human Genome Editing—a meeting that had been called to deliberate about the future of the human species.

Dr. Richi Gill, MD, is back at work, able to enjoy time with his family in the evening and get a good night’s sleep, thanks to research. Three years ago, Gill broke his neck in a boogie board accident while on vacation with his young family. Getting mobile again with the use of a wheelchair is the first thing, Gill says, most people notice. However, for those with a spinal cord injury (SCI), what is happening inside the body also severely affects their quality of life.

You may have heard of Autophagy, it was the beneficiary of a Nobel Prize in 2016 and has been a hot topic since then.

It is credited with such amazing benefits as removing toxic proteins from cells such as which cause Parkinson’s and Alzheimer’s disease, recycling residual proteins, providing energy and building blocks for cells that could still benefit from repair, prompting regeneration for healthy cells, and it may also help with cancer prevention.

COVID-19 may have shocked the city’s commercial market but that hasn’t stopped developers from doing what they do best. In fact, a bevy of newly constructed and redeveloped towers are poised to hit the market in Manhattan.

Industry experts told The Post that it will be those new buildings, designed with cutting-edge tech and with future pandemics in mind, that will have the greatest advantage on the market.

“There is no question the buildings provisioned for the 21st century-plus are going to be in a better position to cash in on the leasing opportunities ahead,” said David Goldstein, vice chairman of real estate services provider Savills. “It could be an older building reimagined, or a new one under construction or in planning stages.”

Micro-sized robots could bring a new wave of innovation in the medical field by allowing doctors to access specific regions inside the human body without the need for highly invasive procedures. Among other things, these tiny robots could be used to carry drugs, genes or other substances to specific sites inside the body, opening up new possibilities for treating different medical conditions.

Researchers at ETH Zurich and Helmholtz Institute Erlangen–Nürnberg for Renewable Energy have recently developed micro and nano-sized robots inspired by biological micro-swimmers (e.g., bacteria or spermatozoa). These , presented in a paper published in Nature Machine Intelligence, are capable of upstream motility, which essentially means that they can autonomously move in the opposite direction to that in which a fluid (e.g., blood) flows. This makes them particularly promising for intervening inside the .

“We believe that the ideas discussed in our multidisciplinary study can transform many aspects of medicine by enabling tasks such as targeted and precise delivery of drugs or genes, as well as facilitating non-invasive surgeries,” Daniel Ahmed, lead author of the recent paper, told TechXplore.

Self-assembly is ubiquitous in the natural world, serving as a route to form organized structures in every living organism. This phenomenon can be seen, for instance, when two strands of DNA—without any external prodding or guidance—join to form a double helix, or when large numbers of molecules combine to create membranes or other vital cellular structures. Everything goes to its rightful place without an unseen builder having to put all the pieces together, one at a time.

For the past couple of decades, scientists and engineers have been following nature’s lead, designing molecules that assemble themselves in , with the goal of making nanostructures, primarily for such as drug delivery or tissue engineering. “These small-molecule-based materials tend to degrade rather quickly,” explains Julia Ortony, assistant professor in MIT’s Department of Materials Science and Engineering (DMSE), “and they’re chemically unstable, too. The whole structure falls apart when you remove the water, particularly when any kind of external force is applied.”

She and her team, however, have designed a new class of small molecules that spontaneously assemble into nanoribbons with unprecedented strength, retaining their structure outside of water. The results of this multi-year effort, which could inspire a broad range of applications, were described on Jan. 21 in Nature Nanotechnology by Ortony and coauthors.

Our goal is audacious — some might even say naive. The aim is to evaluate every gene and drug perturbation in every possible type of cancer in laboratory experiments, and to make the data accessible to researchers and machine-learning experts worldwide. To put some ballpark numbers on this ambition, we think it will be necessary to perturb 20000 genes and assess the activity of 10000 drugs and drug candidates in 20000 cancer models, and measure changes in viability, morphology, gene expression and more. Technologies from CRISPR genome editing to informatics now make this possible, given enough resources and researchers to take on the task.


It is time to move beyond tumour sequencing data to identify vulnerabilities in cancers.